The Tumor Specific Localizing Agents for Radioisotope Image

Kono, Akira; Kojima, Masayasu; Maeda, Takeyasu

doi:10.3769/radioisotopes.21.2_118

Cited by 6 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the absence of BLM, 400 j»M Co(II) did not induce DNA strand breakage either in the dark or under the light. (Nouel et al, 1972;Kono & Kojima, 1972;Poulose et al, 1975;Kahn et al, 1977;Kono et al, 1977) and binds to nuclear DNA (Kono, 1977). Cobalt-57 bleomycin has been used extensively as a radiopharmaceutical to detect cancers in human patients (Poulose et al, 1975;Nouel, 1976;Kahn et al, 1977).…”

Section: Discussionmentioning

confidence: 99%

Light-induced nicking of deoxyribonucleic acid by cobalt(III) bleomycins

Chang

Meares²

1982

Biochemistry

View full text Add to dashboard Cite

The anticancer drug bleomycin is a glycopeptide that causes strand scission of DNA both in vivo and in vitro. Cleavage of DNA by bleomycin has been studied extensively in vitro, with the findings that ferrous ion and molecular oxygen must be present and that addition of reducing agents greatly enhances the reaction. To date, only iron has been shown to be an effective metal cofactor for the cleavage of DNA by bleomycin. Here it is reported that two stable cobalt(III) complexes of bleomycin are strikingly effective in causing single-strand breaks (nicks) in supercoiled DNA in the presence of ultraviolet or visible radiation. For example, 366-nm light from an 18-W long-wavelength mercury lamp for 1 h causes 10(-6) M cobalt(III) bleomycin to completely convert supercoiled phi X174 DNA (10(-8) M DNA, 10(-4) M phosphate) into the nicked circular form. Furthermore, numerous alkali-labile sites are produced on the DNA during this treatment. The observed reactions are not caused by adventitious iron, and they occur only in the presence of cobalt(III) bleomycin and light.

show abstract

Section: Discussionmentioning

confidence: 99%

Light-induced nicking of deoxyribonucleic acid by cobalt(III) bleomycins

Chang

Meares²

1982

Biochemistry

View full text Add to dashboard Cite

show abstract

“…In one case a 57 Co-BLM uptake area near the left adrenal gland was originally considered as a false positive. One year later the patient had a new ' 7 Co-BLM scintigraphy and extensive metastases were observed, including growth at the site of the previous uptake ( Fig. 8 A + B ) .…”

Section: Discussionmentioning

confidence: 99%

“…Today, 14 years after the introduction of 67 Ga (2) and 11 years after ?7 Co-BLM was introduced for tumour scintigraphy (7,9), these radiopharmaceuticals have not found their clarified position in the medical world, despite the fact that they both represent a definite improvement compared to that which was previously possible. A combination of the very rapid development of CT-scanners plus improvements in ultrasound has removed much of the interest in tumour scintigraphy in the hospital.…”

Section: Discussionmentioning

confidence: 99%

The Place of 57Co-Bleomycin in the Evaluation of Tumours

Frederiksen¹,

Rasmussen²,

Flindt-Egebak³

et al. 1983

Nuklearmedizin

View full text Add to dashboard Cite

162 patients were investigated by 57Co-bleomycin scintigraphy. 62 of these patients were also studied with 67Ga. 142 were suspected for malignant neoplastic disease, 20 for a focal inflammatory process. Good visualization with 57Co-bleomycin was obtained in 75% of malignant tumours and in 66% with 67Ga. Most of the patients were studied for abdominal disease and in this region 57Co-bleomycin was found to be qualitatively superior to 67Ga. The principal advantage of 57Co-bleomycin is a very low tissue background specially concerning the bowel. Neither 57Co-bleomycin nor 67Ga are tumour-specific. Both radiopharmaceuticals are taken up by inflammatory processes. This is a disadvantage in tumour diagnostics but the radionuclides can be useful for localizing inflammatory foci. The possibilities of studying the localisation of radionuclides at the cellular level will be discussed.

show abstract